Results of an analysis of 2012 cancer incidence and survival from various cancer registries, published in CDC's Morbidity and Mortality Weekly Report, indicates reduced incidence of overall cancer across the United States.
Launched in December 2010, Healthy People 2020 has an agenda to achieve significant improvement in the health of the population in America by 2020, with disease-specific milestones established along the path. The project aims to reduce the number of new cancer cases, illness, disability, and death from cancer.
As a part of this overall objective, CDC analyzes data across the country, comparing cancer incidence and survival rates and reporting them to the public. The latest report has released analysis of data from the U.S. Cancer Statistics (USCS) for 2012, which is the most recent data available. USCS includes high quality incidence data from CDC’s National Program of Cancer Registries (NPCR) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results program (SEER), survival data from NPCR, and mortality data from the National Vital Statistics System.
Here are the key findings of the report:
The authors attribute the decrease in prostate cancer incidence to the recommendation by the US Preventive Service’s Task Force (USPSTF) against using the prostate-specific antigen (PSA) test for screening men for prostate cancer. Studies recorded an 8% reduction in the use of the PSA test following the USPSTF recommendation: from 32% in 2008 to 24% in 2013.
The authors urge the population—and particularly, the healthcare providers—to follow the new screening recommendations by USPSTF for the various cancers to be able to achieve improved cancer outcomes in the population. Maximizing efforts to prevent cancer, improve adherence to cancer screening recommendations, and assure timely and appropriate cancer care for all persons is needed to achieve the national cancer objectives set forth in Healthy People 2020, they write.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More